Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA

Clinical Rheumatology

Volumn 37, Issue 2, 2018, Pages 315-321

  Iannone, F ^a   Ferraccioli, G ^b   Sinigaglia, L ^c   Favalli, E G ^c   Sarzi Puttini, P ^d   Atzeni, F ^d   Gorla, R ^e   Bazzani, C ^e   Govoni, M ^f   Farina, I ^f   Gremese, E ^b   Carletto, A ^g   Giollo, A ^g   Galeazzi, M ^h   Foti, R ⁱ   Bianchino, L ^j   La Grasta, L ^j   Lapadula, G ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SPEDALI CIVILI   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ UNIVERSITY OF CATANIA   (Italy)

^j ROCHE MILANO RICERCHE   (Italy)

more..

Author keywords

Biologics; Italy; Real world; Registry; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; AMINOTRANSFERASE; ETANERCEPT; INFLIXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; DAS28; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REGISTER; REMISSION; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; PROCEDURES; TREATMENT OUTCOME;

ABATACEPT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; REGISTRIES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85030536637     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-017-3846-8     Document Type: Article

References (49)

1. Aletaha D, Alasti F, Smolen JS (2016) Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis 75:1479–1485
2. Schipper LG, Fransen J, den Broeder AA, Van Riel PL (2010) Time to achieve remission determines time to be in remission. Arthritis Res Ther 12:R97. doi:10.1186/ar3027
3. Bykerk VP, Keystone EC, Kuriya B et al (2013) Achieving remission in clinical practice: lessons from clinical trial data. Clin Exp Rheumatol 31:621–632
4. Monti S, Montecucco C, Bugatti S, Caporali R (2015) Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open 1:e000057. doi:10.1136/rmdopen-2015-000057
5. Smolen JS, Breedveld FC, Burmester GR et al (2015) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-207524
6. Shetty A, Hanson R, Korsten P et al (2014) Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther 8:349–364. doi:10.2147/DDDT.S41437
7. Drugs@FDA: FDA Approved Drug Products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed 16 Dec 2015
8. Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet Lond Engl 354:1932–1939
9. Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602. doi:10.1056/NEJM200011303432202
10. Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141–147. doi:10.1056/NEJM199707173370301
11. Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478–486
12. Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259. doi:10.1056/NEJM199901283400401
13. Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 48:35–45. doi:10.1002/art.10697
14. Klareskog L, van der Heijde D, de Jager JP et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681. doi:10.1016/S0140-6736(04)15640-7
15. van de Putte LBA, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508–516. doi:10.1136/ard.2003.013052
16. Furst DE, Schiff MH, Fleischmann RM et al (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563–2571
17. Kim GW, Lee NR, Pi RH et al (2015) IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res 38:575–584. doi:10.1007/s12272-015-0569-8
18. Mihara M, Kasutani K, Okazaki M et al (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5:1731–1740. doi:10.1016/j.intimp.2005.05.010
19. Maini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829. doi:10.1002/art.22033
20. Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997. doi:10.1016/S0140-6736(08)60453-5
21. Genovese MC, McKay JD, Nasonov EL et al (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968–2980. doi:10.1002/art.23940
22. Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523. doi:10.1136/ard.2008.092932
23. Jones G, Sebba A, Gu J et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96. doi:10.1136/ard.2008.105197
24. Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–1103. doi:10.1136/ard.2007.080002
25. Schiff M, Weinblatt ME, Valente R et al (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86–94. doi:10.1136/annrheumdis-2013-203843
26. Weinblatt ME, Schiff M, Valente R et al (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65:28–38. doi:10.1002/art.37711
27. Gabay C, Emery P, van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541–1550. doi:10.1016/S0140-6736(13)60250-0
28. Buckley F, Finckh A, Huizinga TWJ et al (2015) Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: A network meta-analysis. J Manag Care Spec Pharm 21:409–423
29. Migliore A, Bizzi E, Egan CG et al (2015) Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Ther Clin Risk Manag 11:1325–1335. doi:10.2147/TCRM.S89678
30. Jansen JP, Buckley F, Dejonckheere F, Ogale S (2014) Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs—a systematic review and network meta-analysis. Health Qual Life Outcomes 12:102. doi:10.1186/1477-7525-12-102
31. Yamamoto K, Goto H, Hirao K et al (2015) Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol 42:1368–1375. doi:10.3899/jrheum.141210
32. Genovese MC, Rubbert-Roth A, Smolen JS et al (2013) Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 40:768–780. doi:10.3899/jrheum.120687
33. Romão VC, Santos MJ, Polido-Pereira J et al (2015) Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients: data from the rheumatic diseases Portuguese Register, Reuma.pt. BioMed Res Int 2015:279890. doi:10.1155/2015/279890
34. Leffers HC, Ostergaard M, Glintborg B et al (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70:1216–1222. doi:10.1136/ard.2010.140129
35. Jørgensen TS, Kristensen LE, Christensen R et al (2015) Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatol Oxf Engl. doi:10.1093/rheumatology/kev216
36. Takahashi N, Kojima T, Kaneko A et al (2014) Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clin Rheumatol 33:39–47. doi:10.1007/s10067-013-2392-2
37. Sakai R, Cho S-K, Nanki T et al (2015) Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 17:74. doi:10.1186/s13075-015-0583-8
38. Mariette X, Gottenberg J-E, Ravaud P, Combe B (2011) Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatol Oxf Engl 50:222–229. doi:10.1093/rheumatology/keq368
39. Lapadula G, Ferraccioli G, Ferri C et al (2011) GISEA: an Italian biological agents registry in rheumatology. Reumatismo 63:155–164
40. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F et al (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 34:1670–1673
41. Ferri C, Ferraccioli G, Ferrari D et al (2008) Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 35:1944–1949
42. Atzeni F, Sarzi-Puttini P, Botsios C et al (2012) Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12:225–229. doi:10.1016/j.autrev.2012.06.008
43. Gremese E, Carletto A, Padovan M et al (2013) Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 65:94–100. doi:10.1002/acr.21768
44. Iannone F, Ferraccioli G, Gremese E et al (2014) Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). Ann Rheum Dis 73:e31. doi:10.1136/annrheumdis-2013-205011
45. Iannone F, Gremese E, Gallo G et al (2014) High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clin Rheumatol 33:31–37. doi:10.1007/s10067-013-2348-6
46. Sebastiani M, Anelli MG, Atzeni F et al (2014) Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. Jt Bone Spine Rev Rhum 81:508–512. doi:10.1016/j.jbspin.2014.06.011
47. Iking-Konert C, von Hinüber U, Richter C et al (2015) ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatol Oxf Engl. doi:10.1093/rheumatology/kev372
48. Fortunet C, Pers Y-M, Lambert J et al (2015) Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatol Oxf Engl 54:672–677. doi:10.1093/rheumatology/keu339
49. Ramiro S, Sepriano A, Chatzidionysiou K et al (2017) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101–1136. doi:10.1136/annrheumdis-2016-210708